Review of anti-TL1A therapies for hidradenitis suppurativa with no reported outcomes or safety data
New review looks at anti-TL1A therapies for hidradenitis suppurativa.
This narrative review discusses anti-TL1A therapies, specifically tulisokibart, for hidradenitis suppurativa. However, the source does not r…
A new review explores anti-TL1A therapies for hidradenitis suppurativa, offering fresh insights into treating this painful skin condition.
FDA Approves Cosentyx (secukinumab) for Moderate to Severe Hidradenitis Suppurativa in Adults and Pediatric Patients
The FDA approved a new use for the drug Cosentyx to treat a painful skin condition.
The FDA has approved Cosentyx for moderate to severe hidradenitis suppurativa in adults and pediatric patients 12 years and older. This inte…
The FDA has approved Cosentyx for treating moderate to severe hidradenitis suppurativa, a chronic skin condition that causes painful lumps. …